Apollo Hospitals and Siemens Healthineers have announced a strategic research collaboration aimed at advancing innovations in artificial intelligence (AI) and imaging technologies. The partnership aspires to transform liver disease management in India by enhancing early detection, diagnosis, and monitoring—ultimately improving patient outcomes.
Focus on AI-Driven Liver Disease Solutions
The collaboration will explore areas ranging from quantitative ultrasound imaging to AI-powered clinical tools. These technologies aim to strengthen the entire patient care pathway, from risk stratification and early diagnosis to continuous monitoring and evaluating treatment response.
Addressing India’s Growing Liver Disease Burden
The joint initiative comes at a crucial time. According to Government of India guidelines, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)—previously referred to as NAFLD—is becoming one of the leading causes of liver disease in the country. The condition is particularly prevalent among overweight, obese, and diabetic individuals, affecting anywhere between 9% and 32% of the population. MASLD also increases the risk of cardiovascular disease, currently the leading cause of death in India.
Leveraging Clinical and Technical Expertise
This collaboration brings together Apollo’s clinical acumen and Siemens Healthineers’ technical expertise to develop non-invasive, precise, and patient-centric diagnostic solutions. Sangita Reddy, Joint Managing Director of Apollo Hospitals, emphasized that AI-enabled diagnostics will play a pivotal role in detecting liver fibrosis early, thus allowing for timely and cost-effective interventions.
“Our partnership with Siemens is a leap forward in redefining non-invasive diagnostics. MASLD remains underdiagnosed due to its complexity, and AI models will help us identify the disease earlier and manage it better across the healthcare spectrum,” she stated.
Supporting Precision Population Health Strategies
By integrating AI into clinical decision-making and public health planning, the project aims to support precision population health initiatives. These AI-driven tools will enhance the accuracy and speed of diagnoses while supporting proactive patient management.
Siemens Highlights Technology’s Role in Prevention
Hariharan Subramanian, Managing Director of Siemens Healthcare, highlighted the urgent need for early detection. “Advanced technologies, paired with increased awareness and lifestyle changes, will be key to reversing the rising trend of liver disease in India. Our joint effort with Apollo will address critical gaps in diagnosis and treatment,” he said.
Milestone Agreement Signed in Hyderabad
As reported by Business Standard, the partnership was formalized under a Master Research Agreement (MRA) in March 2025, following a memorandum of understanding signed in 2024. The signing of an MRA addendum on July 23, 2025, in Hyderabad marked a significant milestone. It strengthens their collaborative research in diagnostic and interventional ultrasound imaging.
This alliance marks a major step toward revolutionizing liver disease care in India. It harnesses the power of AI and advanced imaging technologies.